(Repeats to chain to alerts; no changes to text)

Overview

* Rezolute ( RZLT ) fiscal Q4 net loss widens to $24.4 mln from $23.0 mln a yr earlier

* Operating expenses rise due to increased R&D and G&A costs

* Cash and investments increase to $167.9 mln as of June 30, 2025

Outlook

* Rezolute ( RZLT ) expects topline sunRIZE trial results in December 2025

* Company anticipates upLIFT study results in H2 2026

Result Drivers

* R&D EXPENSES - Increased due to higher clinical trial activities, manufacturing costs for ersodetug, and employee-related expenses

* G&A EXPENSES - Rise attributed to professional fees and increased headcount

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q4 EPS -$0.26

Q4 Net -$24.39

Income mln

Q4 -$25.85

Income mln

From

Operatio

ns

Q4 $25.85

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* Wall Street's median 12-month price target for Rezolute Inc ( RZLT ) is $13.00, about 40.6% above its September 16 closing price of $7.72

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)